ASAP3

ASAP3 is a phosphatidylinositol 4,5-bisphosphate-dependent Arf GTPase-activating protein that controls actin cytoskeleton organization, cell migration, and epithelial cell architecture. Its PH domain potentiates catalytic activity toward Arf1, Arf5, and Arf6 by more than 100-fold, and it localizes to focal adhesions where it maintains actin stress fibers, phosphomyosin levels, and γ-actin-1 (ACTG1) stability to drive cell migration and invasion (PMID:18400762, PMID:24284654). In gastric parietal cells, ASAP3 regulates Arf6-GTP levels and microvillar structure; conditional knockout in mice causes microvillar elongation/stacking and substantially reduces gastric acid secretion, a phenotype recapitulated by the small-molecule inhibitor QS11 (PMID:29263912). ASAP3 is transcriptionally induced under hypoxia through direct HIF-1α binding to hypoxia response elements in its promoter (PMID:31410024).

1. 2004 Medium

   Identification of ASAP3 (DDEFL1) as an ArfGAP-domain-containing gene overexpressed in hepatocellular carcinoma established it as a potential growth-promoting factor, but left its enzymatic specificity and cellular mechanism unknown.

   Evidence cDNA microarray, gene transfer, and antisense knockdown with proliferation assays in HCC cells

   PMID:14654939

   Open questions at the time

   • No biochemical characterization of GAP activity or substrate specificity
   • Proliferation phenotype not linked to a specific Arf substrate or downstream pathway
   • Single cell system
2. 2008 High

   Biochemical and cell-biological characterization revealed that ASAP3 is a bona fide ArfGAP with PH-domain-potentiated activity toward Arf1/5/6 and that it localizes to focal adhesions where it is required for stress fiber integrity, phosphomyosin levels, and cell migration/invasion — establishing its core enzymatic and cytoskeletal functions.

   Evidence In vitro GAP assays with purified proteins and domain mutants; siRNA knockdown in mammary carcinoma and glioblastoma cells with immunofluorescence, phalloidin staining, phosphomyosin blotting, and migration/invasion assays

   PMID:18400762

   Open questions at the time

   • Which Arf substrate is the physiologically relevant target in focal adhesions not determined
   • No structural basis for PH-domain potentiation
   • Mechanism linking GAP activity to myosin phosphorylation unknown
3. 2013 Medium

   Discovery that ASAP3 loss destabilizes γ-actin-1 (ACTG1) extended its cytoskeletal role beyond stress fibers, connecting it to actin isoform-specific protein stability.

   Evidence siRNA knockdown of ASAP3 with western blot for ACTG1 and migration/invasion assays

   PMID:24284654

   Open questions at the time

   • Whether ACTG1 stabilization is direct or via an intermediate pathway is unknown
   • Single knockdown approach without rescue
   • Not tested whether other actin isoforms are affected
4. 2017 High

   An in vivo conditional knockout demonstrated a physiological role for ASAP3 in gastric parietal cells: loss of ASAP3 elevates Arf6-GTP, remodels microvilli, and substantially impairs acid secretion — directly linking its GAP activity to an organ-level function.

   Evidence Conditional knockout mouse, electron microscopy of microvilli, GTP-Arf6 pull-down, F-actin staining, and pharmacological validation with the ASAP3 inhibitor QS11

   PMID:29263912

   Open questions at the time

   • Molecular pathway from Arf6-GTP elevation to microvillar remodeling not delineated
   • Whether other ArfGAPs compensate partially in the KO not assessed
   • Contribution of Arf1/Arf5 versus Arf6 in parietal cells not resolved
5. 2017 Low

   Knockdown studies in breast cancer cells suggested ASAP3 influences Rho-family GTPase expression and apoptotic signaling, but the indirect nature of the readouts left the mechanistic link to its ArfGAP activity unresolved.

   Evidence siRNA knockdown with qRT-PCR and western blot for Rho/CDC42/Rac1 and apoptotic markers

   PMID:29348842

   Open questions at the time

   • No reconstitution of direct ASAP3–Rho GTPase interaction; changes may be secondary
   • Single knockdown in one cell line
   • No GAP-dead rescue to confirm dependence on catalytic activity
6. 2019 Medium

   Identification of HIF-1α as a direct transcriptional activator of ASAP3 via HRE elements in its promoter established how ASAP3 is upregulated in hypoxic tumor microenvironments, connecting oxygen sensing to Arf-dependent cytoskeletal remodeling.

   Evidence ChIP for HIF-1α at ASAP3 promoter HREs, luciferase reporter assay, siRNA knockdown, and xenograft rescue experiments in lung adenocarcinoma

   PMID:31410024

   Open questions at the time

   • Whether other hypoxia-responsive transcription factors co-regulate ASAP3 not tested
   • Downstream ASAP3 effector pathway in hypoxic migration not defined
   • Single cancer type studied

• Key unresolved questions include the structural basis for PH-domain potentiation of GAP activity, the identity of the physiologically dominant Arf substrate in different tissue contexts, and the mechanistic link between ArfGAP activity and downstream cytoskeletal/myosin regulatory pathways.
• No crystal structure or cryo-EM of ASAP3 PH–ArfGAP domain interaction
• No genetic separation of Arf1 vs Arf5 vs Arf6 substrate contributions in vivo
• Mechanism coupling Arf-GTP hydrolysis to phosphomyosin and ACTG1 stability unclear